Drugmakers that complain about the growing cost to bring new molecular entities to market aren’t exaggerating, according to a study released last month by the Tufts Center for the Study of Drug Development (CSDD). Even with the initiation of mechanisms to speed drug development such as breakthrough therapy designation and accelerated review, developing a medicine [...]
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers. Now, Weber has one more seat to fill. The Japanese drugmaker's U.S. president is on his [...]
I normally only post Pharma News, but the railing oil is taking is getting to the danger level. Yes, consumers are happy because they can fill their tank for way less than a few months ago, but plummeting oil screams "deflation", sinking world-wide demand, and huge losses for oil companies and hedge funds. Living in [...]
In partnership with activist investor Bill Ackman, the company made a hostile bid to purchase Botox-maker Allergan. Valeant Pharmaceuticals is putting its acquisition growth strategy on hold in favor of reducing debt and boosting its stock price, according to Reuters. Since 2008, Valeant has spent about $19 billion on 40 acquisitions. Now, the company will [...]
Merck ($MRK) may have to rethink its math on the Cubist ($CBST) buyout. Announcing the $9.5 billion transaction Monday, the company pointed to an earnings bump beginning in 2016. But later in the day, a U.S. court nixed all but one of the patents covering its top seller, Cubicin--and that patent expires in 2016. With [...]
Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year. The top 10 deals [...]
ig pharma Merck (NYSE:MRK) agreed to buy antibiotic specialist Cubist Pharmaceuticals (NASDAQ:CBST) Monday in a deal valued at $9.5 billion. Cubist soared 35% in the stock market today, while Merck dropped a fraction. Merck is acquiring Cubist for $102 a share in cash, yielding an equity value of $8.4 billion, plus $1.1 billion in net [...]
The biotech index is more than a triple bagger ramp since 2010. Know that as long as the biopharm has equity (capital), research will continue with reckless abandon. Hopefully, with this ramp, the old guard will implement technology to bring more accurate outcomes. szimm
The biotech index is more than a triple bagger ramp since 2010. As a student of the market for over 20 years, with clinical research funding dropping, is there a top anywhere in sight? SZIMM Exclusive Interview with David Nierengarten, Ph.D., an Analyst at Wedbush Securities Covering the Biotechnology and Biopharmaceuticals Sector TWST: What's the FDA [...]
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. [...]
